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Glucose transportersThe insulin-degrading enzyme (IDE) is a metalloendopeptidase with a high affinity for insulin. Human genetic
polymorphisms in Ide have been linked to increased risk for T2DM. In mice, hepatic Ide ablation causes glucose
intolerance and insulin resistance when mice are fed a regular diet.
Objective: These studies were undertaken to further investigate its regulatory role in glucose homeostasis and
insulin sensitivity in diet-induced obesity.
Methods: To this end, we have compared the metabolic effects of loss versus gain of IDE function in mice fed a
high-fat diet (HFD).
Results:We demonstrate that loss of IDE function in liver (L-IDE-KO mouse) exacerbates hyperinsulinemia and
insulin resistance without changes in insulin clearance but in parallel to an increase in pancreatic β-cell function.
Insulin resistance was associated with increased FoxO1 activation and a ~2-fold increase of GLUT2 protein levels
in the liver of HFD-fedmice in response to an intraperitoneal injection of insulin. Conversely, gain of IDE function
(adenoviral delivery) improves glucose tolerance and insulin sensitivity, in parallel to a reciprocal ~2-fold
reduction in hepatic GLUT2 protein levels. Furthermore, in response to insulin, IDE co-immunoprecipitates
with the insulin receptor in liver lysates of mice with adenoviral-mediated liver overexpression of IDE.
Conclusions:We conclude that IDE regulates hepatic insulin action and whole-body glucose metabolism in diet-
induced obesity via insulin receptor levels.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Insulin-degrading enzyme (IDE), a zinc-metalloendopeptidase that
degrades insulin and glucagon, among other intermediate-size
peptides, is primarily expressed in the cytoplasm of both insulin-
responsive and non-responsive cell types [1–4]. Because of its high
affinity and ability to degrade insulin, IDE had long been presumed to
play a major role in hepatic insulin clearance, a physiological process





. This is an open access article underthrough the liver [1]. This notion was supported by the development
of chronic hyperinsulinemia in mice with pancellular deletion of Ide
(IDE-KO) [5]. Consistent with hyperinsulinemia causing insulin
resistance [1,6], this mouse model also developed marked glucose
intolerance and insulin resistance.
Genetic polymorphisms within or near the Ide locus have been
linked to increased risk for type 2 diabetes mellitus (T2DM) [7–9]. In
addition, there is an association between reduced IDE levels and lower
insulin clearance in T2DM patients [10–12]. The precise cause of
T2DM remains incompletely understood, but insulin resistance, β-cell
function, and insulin clearance have been identified as major culprits.
To delvemore deeply into the IDE's role in the pathogenesis of hepatic
insulin action and glucose homeostasis, we generated a novel mouse
model with exclusive ablation of Ide in hepatocytes (L-IDE-KO). This
mouse model uncovered an important role for IDE in regulating insulin
sensitivity in hepatocytes [13]. L-IDE-KO mice exhibited glucose
intolerance and insulin resistance, but surprisingly hepatic insulinthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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its activation in response to insulin were diminished in L-IDE-KO
hepatocytes, in parallel to a marked reduction in the phosphorylation of
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1),
which promotes receptor-mediated insulin uptake [13]. These
observations provided the impetus for a novel conceptual model
postulating a non-proteolytic function for IDE in the regulation of hepatic
insulin action by cooperating with CEACAM1 in targeting the insulin-IR
complex between intracellular compartments [1,13].
In humans, IDE is expressed in pancreaticβ- andα-cells, with higher
expression in α-cells [14]. In T2DM, IDE protein levels in β-cells are
reduced, but are upregulated by insulin treatment [14]. Interestingly,
targeted ablation of Ide in pancreatic β-cells in vivo (B-IDE-KO mice)
[15] led to constitutive increase in glucose-stimulated insulin secretion
in parallel to upregulation of the high-affinity glucose transporter
GLUT1 from isolated mouse islets and in plasma C-peptide levels of B-
IDE-KO mice [15]. This proposed that IDE is required for functional β-
cell maturity [15].
To further investigate the physiological role of IDE in hepatocytes,
we fed mice a high-fat diet (HFD) and examined the impact of loss
versus gain of IDE function on insulin action and glucose metabolism
in liver.
2. Material and methods
2.1. Mouse studies
Four- to five-week-old male Ideflox/flox;+/+ mice (henceforth,
wildtype-WT) and Ideflox/flox;Alb-Cre/+ (L-IDE-KO) mice were fed
standard rodent chow diet (SD) or a high-fat diet (HFD; Research
Diets D12451, 35% carbohydrates, 45% fat) for 16weeks. Intraperitoneal
glucose tolerance tests (IP-GTT) were conducted after 14 weeks of HFD
feeding, and insulin tolerance tests (IP-ITT) after 15 weeks. Hepatic
insulin clearance (under conditions of fasting-refeeding transition)
was assessed after 13 weeks of HFD feeding, whereas hepatic insulin
clearance (under conditions of steady-state), in the week 16.
Afterwards, mice were euthanized, blood collected, and tissues were
snap-frozen in liquid nitrogen.
For experiments with adenoviral vectors, four-week-old male
C57BL/6J mice were fed a HFD for 4 weeks before adenovirus delivery.
Afterwards, mice were maintained on HFD for 2 additional weeks. IP-
GTT was assessed after 5 weeks of HFD feeding, whereas IP-ITT and
hepatic insulin clearance (under conditions of steady-state) were
assessed in the week 6. Afterwards, mice were euthanized, blood
collected, and tissues were snap-frozen in liquid nitrogen.
Mice were housed in ventilated cages under a 12:12-h light-dark
cycle, and water ad libitum, at the animal facility of the University of
Valladolid (UVa). L-IDE-KO mice were generated and genotyped as we
previously described [13]. The Animal Care and Use Committee of the
UVa approved all experiments (protocol #5003931).
2.2. Plasma biochemistry, hepatic content of triglycerides, and hepatic
glycogen content
Fasting (18 h) and non-fasting (fed ad libitum) blood glucose, and
plasma triglycerides, cholesterol, insulin, C-peptide, and glucagon levels
were assessed as we previously described [13]. Hepatic triglyceride
content was assessed as we previously described [16], and hepatic
glycogen content was assessed using the Glycogen Assay Kit (Sigma-
Aldrich, USA) [13].
2.3. Glucose homeostasis, insulin sensitivity, and insulin clearance studies
To evaluate alterations in glucose homeostasis and insulin sensitivity
in vivo, we performed IP-GTT and IP-ITT, respectively, as described
[13,17]. Hepatic plasma insulin clearance was assessed in two differentways: 1) as the steady-state C-peptide/insulin molar ratio, previously
described by our group [13]. To achieve the steady-state, mice were
fasted from 18:00 PM until 11:00 AM the next morning. 2) During the
fasting-refeeding transition, as described by Kurauti et al. [18,19] with
some modifications, briefly, littermate mice were fasted overnight, re-
fed and blood samples drawn from tail vein at times 0, 60 and
180 min. Plasma insulin and C-peptide levels were assessed as
described in Section 2.2. Then, the C-peptide/insulin molar ratio was
calculated for each time point, and the area under the curve (AUC) at
times 0–60min (AUC0–60), and 60–180min (AUC60–180) was calculated
as a measure of insulin clearance.
To analyze the impact of IDE loss and gain of function on hepatic
insulin signaling, mice were fasted overnight, then administered an i.p
injection of a bolus of insulin (1.5 U/kg) or saline solution, and ten
minutes later, mice were euthanized, and tissues were dissected as we
previously described [13,20].
2.4. Quantitative real-time PCR
Total RNA isolation and cDNA synthesis were performed as described
[13]. mRNA levels were determined by real time qPCR with TaqMan® or
SYBR® Green probe-based assays on a LightCycler® 480 instrument
(Roche) using the 2−ΔΔCt relative quantification method [21]. TaqMan®
Gene Expression assay references (from Applied Biosystems, USA)
were as follows: Mm00473077_m1 for Ide, Mm01247058_m1 for
phosphoenolpyruvate carboxykinase (Pck1), and Mm00839363_m1 for
glucose-6 phosphatase (G6pc). Primers sequences used for SYBR Green
quantitative RT-PCR are in Supplementary Table 1. Expression data
were normalized to the level of the housekeeping gene of the ribosomal
protein L18 (RPL18; Forward: 5′-AAGACTGCCGTGGTTGTGG-3′; Reverse:
5′-AGCCTTGAGGATGCGACTC-3′; Probe: 5′-FAM-TTCCCAAGCTGAAGGT
GTGTGCA-BHQ1-3′).
2.5. Western blot analysis and co-immunoprecipitation
Western blot analyses on isolated mouse tissues, and subcellular
localization of FoxO1 were performed as described [13]. Rabbit anti-
FoxO1 antibody was used as described by Qu et al. [22]. For co-
immunoprecipitation experiments, polyclonal antibodies against IDE
(#AB9210, Millipore, USA) and insulin receptor (#3025, Cell Signaling,
USA) were used to immunoprecipitate proteins from tissue lysates as
previously described [13].
2.6. Mouse islets isolation, analysis of β-cell function, and pancreatic
histomorphometry
Mouse islets were isolated by pancreatic duct perfusion with
collagenase IV (Sigma-Aldrich, USA) and purified as previously reported
[15]. Afterwards, glucose-stimulated insulin secretion (GSIS) was
assessed as described [15]. To assess β-cell function in vivo, mice were
fasted overnight followed by an i.p. injection of a bolus of glucose and
blood sampleswere drawn for 30min. Afterwards, plasma insulin levels
were measured as described above. Then, mice were euthanized and
pancreata dissected, fixed in 10% neutral buffer formalin, paraffin
embedded, and sectioned [15]. For islets histomorphometry, sections
were stained with anti-insulin antibody (Abcam, UK). β-cell mass, the
number of islets, and the mean islets size were quantitated using the
ImageJ software (NIH, USA) as described [13,15].
2.7. Adenoviral vector construction and delivery
Human Ide cDNA was purchased from ImaGenes GmbH (Berlin,
Germany). Ide was amplified using primers flanking the Ide cDNA for
forward reaction (5′-AGCGTTTGCGGTGATCCCGG-3′) and reverse
reaction (5′-CATGCATGGGAAAGTGCAAGTGG-3′), and then cloned
into the adenoviral shuttle plasmid pTG6600. IDE adenoviral vector
3B. Merino et al. / Metabolism Clinical and Experimental 113 (2020) 154352(Ad.IDE) and the control adenovirus null (Ad.null) were generated by
the United Vector Production Unit (Autonomous University of
Barcelona). Adenoviruses (5 × 1012 viral particles/kg of body weight),
diluted in PBS (100 μL), were administered via retro-orbital injection
as described [16].
2.8. Statistical analyses
Statistical analysis was performed using Prism v. 6.0 (GraphPad
Software, Inc., USA). Normality of data was checked with the
Kolmogorov-Smirnov test. Data are presented as means ± SEM.
Comparisons between two groups were done using the unpaired
Student's t-test. Comparisons between more than two groups were
done using the one-way ANOVA. Differences were considered significant
at p b 0.05.
3. Results
3.1. Loss of hepatic IDE function exacerbates glucose intolerance and insulin
resistance in HFD-induced obese mice
To decipher the contribution of IDE to whole-body glucose
homeostasis and insulin sensitivity in the setting of obesity, WT and L-
IDE-KO mice were fed a HFD for 16 weeks. L-IDE-KO mice exhibited aFig. 1. Metabolic features of L-IDE-KO in high-fat obese mice. WT and L-IDE-KO mice were fed
assessed. (A) IP-GTT and area under the curve (AUC) (B). IP-ITT (C) and AUC (D). HOMA index
non-fasting (K) plasma glucose levels. Data are mean ± SEM. n = 8–13 per genotype. *p valuesignificant exacerbation of glucose intolerance and a trend toward
worsening of insulin resistance as compared to WT mice (Fig. 1A-E).
These changes in glucose homeostasis and insulin sensitivity were not
correlated with an increase in body weight, body weight gain, adipose
tissue weight or food intake (Fig. 1F-I). In addition, fasting and non-
fasting blood glucose levels were similar between WT and L-IDE-KO
mice (Fig. 1J-K).
L-IDE-KO mice exhibited significantly increased fasting and non-
fasting plasma insulin levels (Fig. 2A-B) as compared to WT mice, with
a trend toward, but non-statistically significant, increase in fasting and
non-fasting plasma C-peptide levels (Fig. 2C-D). In contrast, fasting
and non-fasting plasma glucagon levels remained unchanged between
L-IDE-KO and WT mice fed HFD (Fig. 2E-F).
L-IDE-KOmice showed similar rates of insulin clearance asWTmice
as measured by steady-state C-peptide/insulin molar ratio (Fig. 3A).
During the fasting-refeeding transition, L-IDE-KO mice exhibited
statistically significant increases in plasma insulin and C-peptide levels
(Fig. 3B-C). However, L-IDE-KO and WT mice showed similar rates of
insulin clearance as measured by C-peptide/insulin molar ratio during
fasting-refeeding transition (Fig. 3D-G). These observations suggest
that elevated plasma insulin levels in L-IDE-KO mice are likely related
to improved β-cell function rather than changes in hepatic insulin
clearance. Histomorphometry analyses of pancreas from WT and L-
IDE-KO mice showed that β-cell mass, islets number, and islets sizehigh-fat diet (HFD) for 16 weeks, and glucose homeostasis and insulin sensitivity were
(E). Body weight (F). Weight gain (G). Fat pad mass (H). Food intake (I). Fasting (J) and
b0.05 vs. WT by Student's t-test or ANOVA.
Fig. 2.Hepatic ablation of Ide augments plasma insulin and C-peptide levels,without altering plasmaglucagon levels. Fasting (A) and non-fasting (B) plasma insulin levels inWTand L-IDE-
KOmice. Fasting (C) and non-fastingC-peptide levels (D). Fasting (E) andnon-fasting glucagon levels (F). Data aremean±SEM. n=7–13per genotype. *p value b0.05 vs.WTby Student's
t-test.
Fig. 3. Hepatic insulin clearance in high-fat obese L-IDE-KO mice. (A) Hepatic insulin clearance measured as the steady-state C-peptide/insulin molar ratio inWT and L-IDE-KO. Data are
mean± SEM. n= 7 per genotype. (B-G) Hepatic insulin clearancemeasured during the fasting-refeeding transition. (B) Plasma insulin levels. (C) Plasma C-peptide levels. (D) C-peptide/
insulin molar ratio in WT and L-IDE-KO mice. (E) AUC between 0 and 180 min of the C-peptide/insulin molar ratio in WT and L-IDE-KO mice. (F) AUC between 0 and 60 min of the C-
peptide/insulin molar ratio in WT and L-IDE-KO mice. (G) AUC between 60 and 180 min of the C-peptide/insulin molar ratio in WT and L-IDE-KO mice. Data are mean ± SEM. n = 12
per genotype. *p value b0.05 vs. WT by Student's t-test.
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assessed ex vivo β-cell function in WT and L-IDE-KO isolated islets. L-
IDE-KO mice exhibited higher insulin content and insulin secretion
per islet than WT mice (Supplementary Fig. 1E-F). Taken together
these results indicate that β-cell function, but not mass, is improved in
L-IDE-KO compared to WT mice, most likely as a compensatory
response to insulin resistance triggered by loss of hepatic IDE function.
3.2. Impact of loss of hepatic IDE function on liver insulin signaling and
glucose transporters in HFD-induced obese mice
To examinewhether insulin resistance observed in L-IDE-KOmice is
associated with altered lipid metabolism, we analyzed circulating and
hepatic lipid content. As shown in Supplementary Fig. 2A-C, fasting
plasma triglycerides, FFAs, and cholesterol levels were comparable in
L-IDE-KO and WT mice. However, L-IDE-KO mice exhibited lower
hepatic triglyceride content compared to WT mice (Supplementary
Fig. 2D). Unaltered expression of lipogenic genes Fasn and Srebp-1c
with elevated expression of genes involved in transporting lipid into
hepatocytes (Fatp1 and Fatp4) and mitochondria for fatty acid β-
oxidation (Cpt1a) in L-IDE-KO mice (Supplementary Fig. 2E-I) suggest
that lower hepatic triglyceride accumulation is likely caused by
increased β-oxidation. These observations rule out any role for lipid
homeostasis in the observed insulin resistance in L-IDE-KO mice.
We had previously reported that liver-specific Ide ablation
significantly lowered insulin receptor (IR) protein and phosphorylation
levels in liver, leading to compromised intracellular insulin signaling
[13]. L-IDE-KOmice exhibited lower hepatic IR protein levels compared
to control mice (Fig. 4A-B). Similarly, phosphorylation of IR was
reduced, although the decrease did not reach statistical significance
(Fig. 4A,C). Interestingly, in L-IDE-KO, insulin stimulation reduced
total hepatic AKT1 protein levels by ~75% (Fig. 4A,E). In contrast, insulin
stimulation did not affect overall AKT2 levels or its phosphorylation inFig. 4. Hepatic ablation of Ide alters multiple intracellular insulin-signaling pathways. (A) Repre
AKT1, AKT2, GSK3α, and GS. Expression of GAPDH was determined to ensure similar protei
arrangement of the figure. Densitometric analyses of the data in panel A. The y-axis represent
total protein in arbitrary units (AU) for IR (B), p-IR (C), p-IR/IR (D), AKT1 (E), p-AKT1Ser473
AKT2Ser474 (K), p-AKT2Ser474/AKT2 (L), GSK3α (M), p-GSK3α (N), p-GSK3α/GSK3α (O), G
genotype and condition. *p value b0.05 vs. saline; $p value b0.05 vs. WT by ANOVA. (S) Rep
GLUT2 (T). Data are mean ± SEM. n = 4 per group. *p value b0.05 vs. WT.the liver of mutant mice (Fig. 4A,J-L). Taken together, these results
demonstrate that ablation of Ide in liver of mice fed a HFD results in
decreased intracellular insulin signaling.
AKT phosphorylates and deactivates glycogen synthase kinase 3
(GSK-3), leading to activation of glycogen synthase (GS) and thus,
inducing glycogen synthesis. We reported that relative to SD-fed WT
mice, basal GSK-3 phosphorylation was higher in L-IDE-KO mice [13].
Similarly, HFD-fed L-IDE-KO mice showed higher basal protein and
phosphorylation levels than WT mice (Fig. 4A, M-N). Interestingly, GS
levels were significantly reduced in L-IDE-KO livers in response to
insulin (Fig. 4A,P). We also explored the functional impact of these
alterations in GSK-3 and GS on liver glycogen levels. As in SD-fed L-
IDE-KOmice [13], hepatic ablation of Ide had no effect on liver glycogen
levels in mice fed HFD (data not shown).
The forkhead box O1 (FoxO1) is a nuclear transcription factor
downstream of AKT that integrates insulin signaling with
gluconeogenesis, which is aberrantly distributed in cellular nuclei,
leading to up-regulation of the gluconeogenic genes Pck1 and G6pc in
SD-fed L-IDE-KO [13]. In bothWT and L-IDE-KOmice fed a HFD, insulin
caused a shift of FoxO1 from the cytoplasmic to the nuclear fraction
(Supplementary Fig. 3A-B). This was correlated with an augmented
up-regulation of G6pc mRNA levels in L-IDE-KO mice compared to
controls (Supplementary Fig. 3C-D).
To further investigate the impact of hepatic IDE loss-of-function on
glucose homeostasis in HFD-induced obese mice, we analyzed hepatic
GLUT2 levels in WT and L-IDE-KO mice. As shown in Fig. 4S-T, hepatic
Ide ablation induced GLUT2 protein levels by ~2-fold.
3.3. Gain of hepatic IDE function improves glucose tolerance and insulin
sensitivity in HFD-induced obese mice
To study the impact of a gain of hepatic IDE function on glucose
homeostasis and insulin sensitivity, C57BL/6J mice were fed a HFDsentative western blots depicting the effects of insulin on total or phosphorylated IDE, IR,
n levels for total liver lysates. Two representative samples have been used for the final
s the ratio of total protein or phosphorylated versus GAPDH, and phosphorylated versus
(F), p-AKT1Thr308 (G), p-AKT1Ser4731/AKT1 (H), p-AKT1Thr308/AKT1 (I), AKT2 (J), p-
S (P), p-GS (Q), p-GS/GS (R) in WT and L-IDE-KO mice. Data are mean ± SEM. n = 5 per
resentative immunoblot using anti-GLUT2 antibodies. Densitometric quantification of
Fig. 4 (continued).
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(Ad)-mediated gene transfer to the liver using a null adenovirus
vector as control [16]. A predetermined dose of IDE vector
(1.5 × 1011 pfu/kg) was used to transduce about 70% of hepatocytes
in liver [16]. This dose induced hepatic IDE protein levels by ~4-fold
after a 2-week period (Fig. 5A). Notably, viral delivery of IDE to liverFig. 5.Hepatic IDE gain-of-function improves glucosemetabolism and insulin sensitivity in high
4 weeks. Mice were then stratified by body weight and assigned randomly to two groups (n =
mediated gene transfer to the liver of mice. Mice were maintained on the HFD for another 2
points indicated below. (A) Hepatic IDE levels (2-weeks after adenoviruses delivery). Upper
Lower panel: Quantification of the ratio of IDE vs. GAPDH in control (Ad.null) and IDE (Ad.ID
control-vector treated mice by Student's t-test. In addition, glucose tolerance (1-week after
assessed in these mice. (B) IP-GTT and area under the curve (C). (D) IP-ITT, and area under th
(I), food intake (J), and epididymal fat pad mass (K). Data are mean ± SEM. n = 7–10 per groresulted in improved glucose tolerance and insulin sensitivity
(Fig. 5B-F) without significant changes in fasting or non-fasting
plasma glucose levels, body weight, or food intake (Fig. 5G-J).
Elevated hepatic IDE production also resulted in a statistically non-
significant trend toward a reduction in fat pad mass compared to
control mice (Fig. 5K).-fat induced obesity. Four-week-oldmale C57BL/6Jmice were fed a high-fat diet (HFD) for
7–10 per group), and human Ide cDNA or control vector were delivered by adenovirus-
weeks (a total of 6 weeks on HFD), and glucose homeostasis was assessed at the time
panel: Representative samples have been used for the final arrangement of the figure.
E) vector treated mice. Data are mean ± SEM. n = 7–10 per group. *p value b0.05 vs.
adenovirus delivery) and insulin sensitivity (2-weeks after adenovirus delivery) were
e curve (E). HOMA index (F). Fasting (G) and non-fasting blood glucose (H). Body weight
up. *p value b0.05 by Student's t-test.
8 B. Merino et al. / Metabolism Clinical and Experimental 113 (2020) 154352In agreement with the observed improvement in glucose tolerance
and insulin sensitivity, hepatic IDE overexpression significantly reduced
non-fasting plasma insulin and C-peptide levels (Fig. 6A-B), with a
statistically non-significant trend toward a reduction in their fasting
levels (Fig. 6C-D). Hepatic IDE overexpression did not affect the
steady-state C-peptide/insulin molar ratio (Fig. 6E), suggesting it does
not impact insulin clearance, nor did it affect fasting and non-fasting
plasma glucagon levels (Fig. 6F-G).
3.4. Impact of hepatic IDE production on liver insulin signaling pathways
and glucose transporters in HFD-induced obese mice
To elucidate the molecular mechanisms underlying the improved
glucose homeostasis and insulin sensitivity by increased hepatic IDE
overexpression, we analyzed circulating and hepatic lipid content.
As shown in Supplementary Fig. 4A-D, plasma triglycerides, FFAs
cholesterol, and hepatic triglyceride levels remained unchanged
between Ad.IDE-treated and Ad.null-treated mice. Together, this
demonstrated that improved hepatic insulin sensitivity was not related
to changes in lipid metabolism.
To analyze the impact of Ad-mediated IDE overexpression on
hepatic insulin signaling, HFD-induced obese mice were fasted
overnight before being i.p injected with insulin (1,5 U/Kg) or saline,
and hepatic protein expression was evaluated. As Fig. 7A-B shows, IDE
overexpression resulted in a reduction in IR protein levels. Surprisingly,Fig. 6. Hepatic IDE gain of function decreases plasma insulin levels without altering insulin cle
treated mice. Fasting insulin (C) and C-peptide plasma levels (D). Hepatic insulin clearance (E
10 per genotype. *p value b0.05 by Student's t-test.insulin-mediated phosphorylation of AKT1 and AKT2 (Fig. 7A, E-L), and
subsequent inactivation of GSK3 (Fig. 7A,M-O) were comparable
between Ad.IDE- and Ad.null-treated mice. However, GS protein and
phosphorylation levels were reduced by ~50% in Ad.IDE-treated
compared to control mice (Fig. 7A,P-R).
We have proposed that IDEmay regulate the intracellular trafficking
of IR independently of its protease activity [1]. To test this hypothesis,
we carried out coimmunoprecipitation experiments to investigate
whether insulin induces the association of IDE with IR. As Fig. 7S-T)
shows, immunoblotting the IR immunopellet with IDE antibody
indicated a marked increase in IR/IDE binding in response to insulin in
Ad.IDE-treated, but not Ad.null-treated mice.
Having shown that loss of hepatic IDE function in HFD-induced
obese mice resulted in 2-fold increase in GLUT2 protein levels (Fig. 4S-
T), we then analyzed the impact of hepatic IDE overexpression on
GLUT2 in HFD-induced obese mice. As shown in Fig. 8A-B, hepatic IDE
overexpression resulted in ~2-fold reduction of GLUT2 protein levels
with a reciprocal 2-fold increase in GLUT1 protein levels (Fig. 8A-C),
altering hepatic GLUT1/GLUT2 ratio (Fig. 8D).
4. Discussion
In an earlier study, we demonstrated that L-IDE-KO mice fed a
regular diet exhibited insulin resistance and glucose intolerance with
no change in circulating insulin levels [13]. The current study providesarance. Non-fasting insulin (A) and C-peptide (B) plasma levels in control and IDE-vector
). Fasting (F) and non-fasting (G) glucagon plasma levels. Data are mean ± SEM. n = 7–
9B. Merino et al. / Metabolism Clinical and Experimental 113 (2020) 154352in vivo evidence that liver-specific deletion of IDE worsens insulin
resistance and glucose intolerance in the setting of HFD-induced obesity
with a parallel increase in plasma insulin levels. Thus, liver-specific
deletion of Ide causes chronic hyperinsulinemia in the presence of
HFD-induced obesity.
In our L-IDE-KO mouse model in HFD-induced obesity,
hyperinsulinemia may be interpreted as a compensatory mechanism
to counter peripheral insulin resistance, in part associated with reducedFig. 7. Effect of hepatic IDE production on insulin signaling pathways and the insulin-IR-c
phosphorylated IR, AKT1, AKT2, GSK3α, and GS. Expression of GAPDH was determined to en
used for the final arrangement of the figure. Densitometric analyses of the data in panel A.
phosphorylated versus total protein in arbitrary units (AU) for IR (B), p-IR (C), p-IR/IR (D), AK
AKT1 (I), AKT2 (J), p-AKT2Ser474 (K), p-AKT2Ser474/AKT2 (L), GSK3α (M), p-GSK3α (N), p
mean ± SEM. n = 3–6 per genotype and condition. *p value b0.05, $p value b0.05 by ANOVA
with Ad.null or Ad.IDE vectors were subjected to immunoprecipitation with α-IR followed
quantification of co-immunoprecipitation of IDE and IR. Data are mean ± SEM n= 3 independinsulin clearance as expected from a protease that, for the last decades,
has been postulated to play a major role in hepatic insulin degradation
[23,24]. Several studies have shown that chronic hyperinsulinemia
emerges, at least in part, from lower rates of insulin clearance to
compensate for peripheral insulin resistance in individuals with obesity
or T2DM [11,25–29]. Furthermore, some authors have shown a
relationship between reduced insulin clearance and diminished hepatic
IDE activity in individuals with obesity or T2DM [10,30]. Likewise,omplex. (A) Representative western blots depicting the effects of insulin on total or
sure similar protein levels for total liver lysates. Two representative samples have been
The y-axis represents the ratio of total protein or phosphorylated versus GAPDH, and
T1 (E), p-AKT1Ser473 (F), p-AKT1Thr308 (G), p-AKT1Ser4731/AKT1 (H), p-AKT1Thr308/
-GSK3α/GSK3α (O), GS (P), p-GS (Q), p-GS/GS (R) in WT and L-IDE-KO mice. Data are
. Co-immunoprecipitation of IDE and IR. Aliquots of liver lysates from mice transduced
by immunoblotting with α-IDE antibody. (S) Western blot images. (T) Densitometric
ent experiments. *p value b0.05 by Student's t-test.
Fig. 7 (continued).
10 B. Merino et al. / Metabolism Clinical and Experimental 113 (2020) 154352rodentmodels fed different high-fat diets have been used to investigate
the relationship between insulin clearance and IDE activity. However,
the use of diverse experimental models fed diets with differing fat
composition and for varying lengths of time has yielded no consensus
or conclusive evidence concerning the cause-effect relationship
between IDE activity and insulin clearance in the setting of obesity
and diabetes [31–33].
To clarify the cause-effect relationship between IDE and insulin
clearance in the setting of obesity, we have compared the effect of
reduced versus increased IDE expression in hepatocytes on insulin
clearance and action. Neither the loss (L-IDE-KO mouse) nor the gain
(adenoviral delivery) of IDE function altered the hepatic insulin
clearance rate (measured as the steady-state C-peptide/insulin molar
ratio in fasting or during the fasting-refeeding transition) in HFD-
induced obesity. In fact, our results indicate that the hyperinsulinemia
observed in L-IDE-KO mice is more significantly related to enhanced
β-cell function and insulin secretion rather than reduced insulinclearance. Our data are in agreement with our previous studies using
L-IDE-KO fed a standard chow diet demonstrating that IDE is not a
major player in hepatic insulin extraction [13]. Nonetheless, we
acknowledge that a limitation of this study is that we do not assess
hepatic insulin clearance by hyperinsulinemic-euglycemic clamp
analysis [34]. Further research using this technique in L-IDE-KO mice
is warranted to clarify the role of IDE on hepatic insulin clearance.
In collaboration with the Najjar group [1], we have recently
proposed a newmodel for hepatic insulin clearance, inwhich CEACAM1
and IDE coordinately regulates IR trafficking as it transports insulin
through intracellular endosomal compartments to ultimately target it
to the degradation pathways before it recycles to the membrane.
According to thismodel, CEACAM1promotes receptor-mediated insulin
endocytosis and targeting it to the degradation process, while IDE
participates in its intracellular trafficking at different steps. These
include IR stabilization upon insulin binding, microtubule
reorganization and polymerization to remove CEACAM1 from the
Fig. 8. Hepatic gain of IDE function changes the ratio GLUT1/GLUT2 in HFD-induced obesity. (A) Representative immunoblot using anti-GLUT2 and anti-GLUT1 antibodies. Expression of
GAPDHwas determined to ensure similar protein levels for total liver lysates. Densitometric quantification of GLUT2 (B) and GLUT1 (C). Ratio GLUT1/GLUT2 (D). Data aremean± SEM. n
= 4 per group. *p value b0.05 by Student's t-test.
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IR and/or to regulate vesicular trafficking of IR back to the plasma
membrane [1]. The current studies provide a first test of this model
demonstrating an increase in the association between IDE and IR in
response to insulin. This finding lends support to the notion that IDE
forms complexes with the IR to regulate its intracellular endosomal
trafficking. Intriguingly, both loss-of-function and gain-of-function
manipulations to hepatic IDE resulted in lower total protein levels of the
IR. We hypothesize that these antipodal outcomes emerge as follows:
Depleting IDE reduces IR recycling, whereas IDE overexpression speeds
up IR turnover, both leading to lower IR protein levels. Nonetheless, the
opposing effects of the loss and gain of IDE function on insulin and glucose
tolerance is consistent with a role for IDE in promoting insulin sensitivity
in liver. Of interest, IR is expressed as two isoforms (IR-A and IR-B) with
the former being less abundant but with higher affinity for insulin.
Whether IDE has a differential effect on insulin uptake and intracellular
trafficking via these two forms is not yet known, but this possibility
may mediate the differential effect of loss- versus gain-of-function
changes to IDE on hepatic insulin sensitivity and glucose tolerance.
Further research is warranted to identify the mechanism(s) underlying
the regulation of insulin sensitivity by IDE.
The notion that IDE participates as a scaffold protein regulating
membrane-bound and nuclear receptors arises from ample experimental
evidence showing that IDE associates with the cytoplasmic domain of the
macrophage Type A scavenger receptor [35], and with androgen and
glucocorticoid receptors [36]. We recently demonstrated that genetic
depletion of Ide in pancreatic β-cells in vivo resulted in ~60% increase
protein levels of GLUT1, in parallel with constitutive insulin secretion
[15]. Surprisingly, we found that hepatic overexpression of IDE increases
total GLUT1 protein levels by ~2-fold. We hypothesized that the increase
inGLUT1 levels is a compensatory change that accelerates hepatic glucose
uptake andmetabolism, in response to decrease in hepatic GLUT2 protein
levels in in Ad.IDE-treated mice.
Similarly, we show that genetic manipulation of Ide in liver resulted
in changes in the level of GLUT2, a major low-affinity glucose
transporter in the plasma membrane of hepatocytes [37], but
dispensable for glucose output [38]. Despite its well-accepted role in
glucose uptake during the absorptive phase, it has been assigned otherfunctions. Hepatic ablation of Slc2a in mice revealed that GLUT2 is
necessary for physiological control of glucose-sensitive genes, and its
inactivation leads to impaired glucose-stimulated insulin secretion,
linking hepatic glucose sensing to the long-preservation of pancreatic
β-cell function by a mechanism likely involving bile acids [39,40].
Thus, the liver-β-cell axis controls β-cell secretion capacity, and an
altered glucose metabolism in hepatocytes induces progressive β-cell
dysfunction, independently of β-cell mass and insulin content [39,40].
On the other hand, GLUT2 is present in glucose-sensing cells of the
hepatoportal vein region, which is richly innervated by vagal afferents.
Following intestinal glucose absorption, GLUT2 acts as a glucose-
sensor inducing a nervous signal that stimulates first-phase insulin
secretion [41,42]. Interestingly, in the liver IDE is present in
parenchymal cells, particularly near the portal tract, and in the
epithelium of the bile duct [43]. In our loss-of-function model, higher
GLUT2 protein levels paralleled increased insulin secretion,
independently of β-cell mass. Conversely, in the gain-of-function
model, lower GLUT2 protein levels paralleled reduced insulin secretion.
The role of hepatic IDE in the regulation of β-cell function through the
liver-β-cell axis awaits experimental examination.
5. Conclusions
In the setting of obesity, the current studies show that loss of IDE
function aggravates insulin resistance and glucose intolerance,
suggesting that pharmacological inhibition of IDE is contraindicated in
the treatment of T2DM, as has been debated [1,44]. Together with the
demonstration that gain of IDE function exerts beneficial effects on
glucose tolerance and insulin sensitivity in the setting of obesity, this
provides a strong rationale for developing pharmacological compounds
targeting IDE activation in the treatment of T2DM.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.metabol.2020.154352.
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